Search
for
Sort by
Research 721–750 of 1000+
- Development of growth factor-incorporating liposomes for integration into scaffolds as a method to improve tissue regeneration
- Skin manifestations of endocrine diseases
- HIBISCUS ROSA-SINENSIS AND AZADIRACHTA INDICA HEALING FOR GETTING SKIN INFLAMMATION NATURALLY: A REVIEW
- Alopecia Areata: Current Review
- Alopecia Areata: A tissue specific autoimmune disease of the hair follicle
- Prostaglandin-Induced Hair Growth
- Lichen Planopilaris: Update on Diagnosis and Treatment
- Gender differences in skin: A review of the literature
- Alopecia areata
- Microneedles as the technique of drug delivery enhancement in diverse organs and tissues
- Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management
- Aging of hair
- THE PATHOGENESIS OF ALOPECIA AREATA
- Alopecia Areata Update
- Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature
- What causes hidradenitis suppurativa ?—15 years after
- Clinical and biological impact of the exposome on the skin
- Niosomes as a propitious carrier for topical drug delivery
- Dermatophytosis in companion animals: A review
- Neuronal plasticity of the “brain–skin connection”: stress-triggered up-regulation of neuropeptides in dorsal root ganglia and skin via nerve growth factor-dependent pathways
- Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
- Alopecia areata update
- TOXIC EPIDERMAL NECROLYSIS
- Lipid levels in patients with lichen planus: a case-control study
- Vasoactive intestinal peptide, whose receptor-mediated signalling may be defective in alopecia areata, provides protection from hair follicle immune privilege collapse
- The lack of significant changes in scalp hair follicle density with advancing age
- Alopecia areata: A review
- The Basic Science of Hair Biology
- Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases
- Dermatological manifestations associated with COVID‐19: A comprehensive review of the current knowledge